ELAN Q2 2025 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.2B+4.8% YoY

Gross Profit

$577M46.5% margin

Operating Income

$85M6.8% margin

Net Income

$11M0.9% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+4.0%

Cash Flow

Operating Cash Flow

$237M

Free Cash Flow

$180M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$13.7B

Total Liabilities

$7.0B

Stockholders' Equity

$6.8B

Cash & Equivalents

$539M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.2B	$1.2B	+4.8%
Gross Profit	$577M	$558M	+3.4%
Operating Income	$85M	$115M	-26.1%
Net Income	$11M	-$50M	+122.0%

Revenue Segments

Pet Health

$643M35%

Farm Animal

$583M32%

Cattle

$268M15%

Poultry

$215M12%

Swine

$100M5%

Contract Manufacturing

$15M1%

Geographic Segments

Non-US

$648M52%

UNITED STATES

$593M48%